CRANBURY, N.J., June 17, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,547,170 shares of common stock. As a result, the Company issued a total of 19,528,302 shares in the offering at a price of $13.25 per share.
The gross proceeds from the offering to Amicus are expected to be $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Cowen and Company, LLC acted as lead manager and Janney Montgomery Scott LLC acted as co-manager for the offering.
The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for Galafold™ (migalastat) for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.
Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number: 866-803-9204) or Goldman, Sachs & Co., by mail, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile: 212-902-9316, by email: email@example.com; or by telephone: 866-471-2526.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. Amicus' lead programs in development include the small molecule pharmacological chaperone Galafold™ for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I.
Statements in this press release concerning Amicus' future expectations, plans and prospects, including, without limitation, statements regarding the use of proceeds from the public offering, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements due to various risks, uncertainties and important factors, including those set forth in the "Risk Factors" section in the prospectus supplement relating to the offering and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission, any of which could cause its actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
CONTACT: Investors/Media: Amicus Therapeutics Sara Pellegrino Director, Investor Relations firstname.lastname@example.org (609) 662-5044 Media: Pure Communications Dan Budwick email@example.com (973) 271-6085
Source:Amicus Therapeutics, Inc.